Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Lymphangioleiomyomatosis × Hydroxychloroquine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 5 Prostatic Neoplasms 3 Multiple Myeloma 3 Colorectal Neoplasms 3 Unspecified Adult Solid Tumor, Protocol Specific 2 Rectal Neoplasms 2 Neoplasms, Plasma Cell 2 Neoplasms 2 Glioblastoma 2 Colonic Neoplasms 2 Solid Tumor 1 Sarcoma, Clear Cell 1 Refractory or Relapsed Solid Tumors 1 Platinum-resistant Epithelial Ovarian Cancer 1 Neoplasm Metastasis 1 Melanoma 1 Malignant Solid Tumour 1 Lymphangioleiomyomatosis 1 Liver Neoplasms 1 Klatskin Tumor 1 Gliosarcoma 1 Gastrointestinal Neoplasms 1 Cholangiocarcinoma 1 Central Nervous System Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Arthritis, Rheumatoid 1 Anatomic Stage I Breast Cancer AJCC v8 1 Adult Solid Neoplasm 1 Adenocarcinoma 1

Interventions

Sirolimus 6 Everolimus 3 saracatinib 1 Urination 1 Sugars 1 Simvastatin 1 Resveratrol 1 Octreotide 1 Letrozole 1 Imatinib Mesylate 1 Hydroxychloroquine 1 Doxycycline 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01687179 2018-10-11

SAIL

Brigham and Women's Hospital

Phase 1 Completed

14 enrolled 14 charts

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡